Abstract | PURPOSE: METHODS: This 3-period crossover study enrolled healthy subjects. In periods 1 and 2, subjects received i.v. placebo either alone or with open-label oral moxifloxacin. In period 3, subjects received a single dose of temsirolimus 25 mg. The primary statistical objective was to estimate the effect of temsirolimus compared with placebo on change from time-matched baseline QTc at the end of infusion (0.5 h). Assay sensitivity was evaluated by the effect of moxifloxacin on change from time-matched baseline QTc compared with placebo. RESULTS: In total, 58 subjects were enrolled. Temsirolimus had no effect on QTc interval in the primary analysis. At 11 of 12 secondary time points, the upper bound for the temsirolimus QTc 90% confidence intervals for the time-matched change from baseline difference from placebo was <10 ms, with no evidence of QTc trends or relationship to concentrations of temsirolimus or its major metabolite, sirolimus. Moxifloxacin, the positive control, produced a significant increase in the QTc interval compared with placebo 0.5-4 h post-dose (P < 0.0001). No subject had a QTc interval exceeding 450 ms or a change from baseline of >30 ms. CONCLUSIONS: Therapeutic exposure to temsirolimus is not associated with clinically significant changes in QTc intervals in healthy adults.
|
Authors | Joseph P Boni, Cathie Leister, Bruce Hug, Jaime Burns, Daryl Sonnichsen |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 69
Issue 6
Pg. 1433-42
(Jun 2012)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 22367193
(Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Infective Agents
- Antineoplastic Agents
- Aza Compounds
- Cytochrome P-450 CYP3A Inhibitors
- Fluoroquinolones
- Placebos
- Protein Kinase Inhibitors
- Quinolines
- temsirolimus
- Cytochrome P-450 CYP3A
- CYP3A4 protein, human
- Moxifloxacin
- Sirolimus
|
Topics |
- Adolescent
- Adult
- Anti-Infective Agents
(pharmacology)
- Antineoplastic Agents
(pharmacology)
- Aza Compounds
(pharmacology)
- Cross-Over Studies
- Cytochrome P-450 CYP3A
- Cytochrome P-450 CYP3A Inhibitors
- Electrocardiography
(drug effects)
- Female
- Fluoroquinolones
- Humans
- Male
- Middle Aged
- Moxifloxacin
- Placebos
- Protein Kinase Inhibitors
(pharmacology)
- Quinolines
(pharmacology)
- Single-Blind Method
- Sirolimus
(adverse effects, analogs & derivatives, pharmacokinetics, pharmacology)
|